Skip to main content

How we treat

This Journal of Hematology & Oncology series will focus on guidelines, consensus, and multidisciplinary approaches on cancers and blood disorders. All submissions to this series need to be pre-approved.

Prospective authors should contact the Editorial Office for pre-approval with the outline of their paper, the lead author name, and institution.

Manuscripts sponsored by pharmaceutical companies will not be considered.

Articles published in the collection have already gone through the systematic peer review process of the journal.

© xixinxing / Fotolia.

  1. Sickle cell disease (SCD), which affects approximately 100,000 individuals in the USA and more than 3 million worldwide, is caused by mutations in the βb globin gene that result in sickle hemoglobin production...

    Authors: A. M. Brandow and R. I. Liem
    Citation: Journal of Hematology & Oncology 2022 15:20
  2. The consensus recommendations in 2018 from The Chinese Society of Hematology (CSH) on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation (allo-HSCT) f...

    Authors: Xiao-hui Zhang, Jing Chen, Ming-Zhe Han, He Huang, Er-lie Jiang, Ming Jiang, Yong-rong Lai, Dai-hong Liu, Qi-Fa Liu, Ting Liu, Han-yun Ren, Yong-Ping Song, Zi-min Sun, Xiao-wen Tang, Jian-min Wang, De-pei Wu…
    Citation: Journal of Hematology & Oncology 2021 14:145
  3. Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a heterogeneous group of malignancies sharing similar disease courses and treatment paradigms. Most patients with iNHL have an ex...

    Authors: Melissa Lumish, Lorenzo Falchi, Brandon S. Imber, Michael Scordo, Gottfried von Keudell and Erel Joffe
    Citation: Journal of Hematology & Oncology 2021 14:5